Thermo Fisher Scientific (TMO) Given Consensus Recommendation of “Buy” by Analysts

Shares of Thermo Fisher Scientific (NYSE:TMO) have been assigned an average rating of “Buy” from the eighteen ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $220.08.

A number of brokerages recently weighed in on TMO. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Leerink Swann reaffirmed an “outperform” rating and set a $239.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. ValuEngine raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Finally, Bank of America boosted their price objective on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, February 1st.

How to Become a New Pot Stock Millionaire

Shares of NYSE:TMO opened at $219.53 on Thursday. The company has a quick ratio of 0.92, a current ratio of 1.34 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific has a fifty-two week low of $152.92 and a fifty-two week high of $226.44. The stock has a market cap of $86,749.20, a P/E ratio of 23.13, a price-to-earnings-growth ratio of 1.59 and a beta of 1.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, beating analysts’ consensus estimates of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same quarter in the prior year, the firm earned $2.41 EPS. The company’s revenue for the quarter was up 22.1% compared to the same quarter last year. equities analysts expect that Thermo Fisher Scientific will post 10.84 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, April 16th. Shareholders of record on Thursday, March 15th were given a $0.17 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend was Wednesday, March 14th. This represents a $0.68 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio is 7.17%.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $204.60, for a total value of $511,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Gregory J. Herrema sold 33,327 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the sale, the senior vice president now directly owns 60,471 shares of the company’s stock, valued at $13,285,478.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 88,827 shares of company stock valued at $19,012,672. 0.49% of the stock is owned by insiders.

Several large investors have recently modified their holdings of the company. Chemical Bank lifted its stake in shares of Thermo Fisher Scientific by 17.4% in the 4th quarter. Chemical Bank now owns 14,485 shares of the medical research company’s stock worth $2,751,000 after acquiring an additional 2,148 shares during the period. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Thermo Fisher Scientific by 16.4% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 12,330 shares of the medical research company’s stock worth $2,341,000 after acquiring an additional 1,737 shares during the period. D.B. Root & Company LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $213,000. KCM Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 28.8% in the 4th quarter. KCM Investment Advisors LLC now owns 3,883 shares of the medical research company’s stock worth $737,000 after acquiring an additional 869 shares during the period. Finally, Xact Kapitalforvaltning AB lifted its stake in shares of Thermo Fisher Scientific by 6.8% in the 4th quarter. Xact Kapitalforvaltning AB now owns 85,954 shares of the medical research company’s stock worth $16,321,000 after acquiring an additional 5,509 shares during the period. 87.62% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://weekherald.com/2018/04/19/thermo-fisher-scientific-tmo-given-consensus-recommendation-of-buy-by-analysts.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply